There is new, compelling evidence to suggest that all men who use testosterone therapy products have an increased risk of life-threatening blood clots. This remains true regardless of whether the patients have been diagnosed with hypogonadism or not. Testosterone therapy products, which include Axiron, Androgel, and Testim, have been under... Read more »

Hundreds of testosterone lawsuits have been officially resolved now that the master settlement agreement has been finalized, as of late July 2018. The settlement agreement only applies to Androderm lawsuits filed against Actavis and Allergan. Thousands of other testosterone lawsuits have been filed against other manufacturers in recent years. This... Read more »

Actavis, the makers of Androderm, has announced that there is a tentative settlement agreement in place that would resolve roughly 500 lawsuits. The plaintiffs involved with the litigation allege that they suffered serious complications as a result of their use of the defendants’ medicated testosterone patch. Actavis, which was acquired... Read more »

Hundreds of plaintiffs and the defendant, Eli Lilly and Company, reached a global settlement agreement that resolves all federally filed Axiron lawsuits pending against the pharmaceutical giant. The move prompted the U.S. District Court for the Northern District of Illinois, which had been overseeing the multidistrict litigation (MDL), to vacate... Read more »

Several very large jury verdicts against the makers of Androgel, AbbVie, caused the U.S. District Judge in charge of Federal multidistrict litigation (MDL) in a number of Androgel trials to order the parties involved to attend a conference in early November to talk about settlement negotiation status. AbbVie Ordered to... Read more »

Testosterone supplementation for older men has become big business for companies like Abbott Laboratories and AbbVie as they have marketed their testosterone products to the general population. Unfortunately, the benefits touted by these manufacturers may be overstated, new studies are finding. In fact, the risks associated with testosterone therapy might... Read more »

Eight Androgel lawsuits have been selected out of around 5,500 cases currently pending to serve as bellwether trials in the coordinated litigation. The bellwether trials are carefully selected to provide insight into how juries might respond to evidence and testimony in future trials. These early trials also can serve as... Read more »

An Arlington, Texas man has filed a testosterone lawsuit against Endo Pharmaceuticals, Inc., Auxilium Pharmaceuticals, Inc. and GlaxoSmithKline, LLC. His lawsuit will join the multidistrict litigation in the Northern District of Illinois. According to his short form complaint, the man was prescribed and began taking Testim in June 2010. In... Read more »

  U.S. District Judge Matthew Kennelly of the Northern District of Illinois has issued a schedule of bellwether trials for six Androgel lawsuits. The trials are expected to begin in April and conclude in November of 2017. The issuance of this schedule rejected a request by the defendants to bifurcate... Read more »

The first bellwether trials in multidistrict litigation 2545, which concerns injuries allegedly caused by testosterone replacement therapy, are slated to go to trial by fall of 2016. Court dockets show that more than 2,700 complaints are currently pending against the manufacturers of Testim, Adroderm, Androgel, Axiron and other products that... Read more »